{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma%2C+Non-Small-Cell+Lung+Cancer&page=29",
    "query": {
      "condition": "Carcinoma, Non-Small-Cell Lung Cancer",
      "page": 29
    },
    "page_size": 10
  },
  "pagination": {
    "page": 29,
    "page_size": 10,
    "total_count": 3652,
    "total_pages": 366,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma%2C+Non-Small-Cell+Lung+Cancer&page=30&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma%2C+Non-Small-Cell+Lung+Cancer&page=28&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-15T03:46:54.112Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03819296",
      "title": "Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Clinical Stage 0 Cutaneous Melanoma AJCC v8",
        "Clinical Stage I Cutaneous Melanoma AJCC v8",
        "Clinical Stage IA Cutaneous Melanoma AJCC v8",
        "Clinical Stage IB Cutaneous Melanoma AJCC v8",
        "Clinical Stage II Cutaneous Melanoma AJCC v8",
        "Clinical Stage IIA Cutaneous Melanoma AJCC v8",
        "Clinical Stage IIB Cutaneous Melanoma AJCC v8",
        "Clinical Stage IIC Cutaneous Melanoma AJCC v8",
        "Clinical Stage III Cutaneous Melanoma AJCC v8",
        "Clinical Stage IV Cutaneous Melanoma AJCC v8",
        "Colitis",
        "Lung Non-Small Cell Carcinoma",
        "Malignant Genitourinary System Neoplasm",
        "Malignant Solid Neoplasm",
        "Pathologic Stage 0 Cutaneous Melanoma AJCC v8",
        "Pathologic Stage I Cutaneous Melanoma AJCC v8",
        "Pathologic Stage IA Cutaneous Melanoma AJCC v8",
        "Pathologic Stage IB Cutaneous Melanoma AJCC v8",
        "Pathologic Stage II Cutaneous Melanoma AJCC v8",
        "Pathologic Stage IIA Cutaneous Melanoma AJCC v8",
        "Pathologic Stage IIB Cutaneous Melanoma AJCC v8",
        "Pathologic Stage IIC Cutaneous Melanoma AJCC v8",
        "Pathologic Stage III Cutaneous Melanoma AJCC v8",
        "Pathologic Stage IIIA Cutaneous Melanoma AJCC v8",
        "Pathologic Stage IIIB Cutaneous Melanoma AJCC v8",
        "Pathologic Stage IIIC Cutaneous Melanoma AJCC v8",
        "Pathologic Stage IIID Cutaneous Melanoma AJCC v8",
        "Pathologic Stage IV Cutaneous Melanoma AJCC v8",
        "Stage 0 Lung Cancer AJCC v8",
        "Stage I Lung Cancer AJCC v8",
        "Stage IA1 Lung Cancer AJCC v8",
        "Stage IA2 Lung Cancer AJCC v8",
        "Stage IA3 Lung Cancer AJCC v8",
        "Stage IB Lung Cancer AJCC v8",
        "Stage II Lung Cancer AJCC v8",
        "Stage IIA Lung Cancer AJCC v8",
        "Stage IIB Lung Cancer AJCC v8",
        "Stage III Lung Cancer AJCC v8",
        "Stage IIIA Lung Cancer AJCC v8",
        "Stage IIIB Lung Cancer AJCC v8",
        "Stage IIIC Lung Cancer AJCC v8",
        "Stage IV Lung Cancer AJCC v8",
        "Stage IVA Lung Cancer AJCC v8",
        "Stage IVB Lung Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Best Practice",
          "type": "OTHER"
        },
        {
          "name": "Biospecimen Collection",
          "type": "OTHER"
        },
        {
          "name": "Endoscopic Procedure",
          "type": "PROCEDURE"
        },
        {
          "name": "Fecal Microbiota Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Infliximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Vedolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "OTHER",
        "PROCEDURE",
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 800,
      "start_date": "2021-02-21",
      "completion_date": "2026-10-31",
      "has_results": false,
      "last_update_posted_date": "2026-07-15",
      "last_synced_at": "2026-10-15T03:46:54.112Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03819296"
    },
    {
      "nct_id": "NCT01892046",
      "title": "Safety and Pharmacology of SNX-5422 Plus Carboplatin and Paclitaxel in Subjects With Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "SNX-5422",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Esanex Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2013-11",
      "completion_date": "2017-07",
      "has_results": false,
      "last_update_posted_date": "2017-07-26",
      "last_synced_at": "2026-10-15T03:46:54.112Z",
      "location_count": 4,
      "location_summary": "Washington D.C., District of Columbia • Augusta, Georgia • Hackensack, New Jersey + 1 more",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01892046"
    },
    {
      "nct_id": "NCT04725188",
      "title": "Pembrolizumab/Vibostolimab Coformulation (MK-7684A) or Pembrolizumab/Vibostolimab Coformulation Plus Docetaxel Versus Docetaxel for Metastatic Non Small Cell Lung Cancer (NSCLC) With Progressive Disease After Platinum Doublet Chemotherapy and Immunotherapy (MK-7684A-002, KEYVIBE-002)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Non Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab/Vibostolimab coformulation",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 255,
      "start_date": "2021-04-20",
      "completion_date": "2024-10-17",
      "has_results": true,
      "last_update_posted_date": "2025-08-15",
      "last_synced_at": "2026-10-15T03:46:54.112Z",
      "location_count": 10,
      "location_summary": "Los Angeles, California • Peoria, Illinois • Lexington, Kentucky + 7 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Peoria",
          "state": "Illinois"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Hattiesburg",
          "state": "Mississippi"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04725188"
    },
    {
      "nct_id": "NCT01820754",
      "title": "Evaluation of Circulating T Cells and Tumor Infiltrating Lymphocytes (TILs) During / After Pre-Surgery Chemotherapy in Non-Small Cell Lung Cancer (NSCLC)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Ipilimumab",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel, Cisplatin, Carboplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2013-03",
      "completion_date": "2018-04-30",
      "has_results": true,
      "last_update_posted_date": "2021-02-26",
      "last_synced_at": "2026-10-15T03:46:54.112Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01820754"
    },
    {
      "nct_id": "NCT03421353",
      "title": "AZD9150 Plus Durvalumab Alone or in Combination With Chemotherapy in Patients With Advanced, Solid Tumours and in Patients With Non-Small-Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumours"
      ],
      "interventions": [
        {
          "name": "AZD9150",
          "type": "DRUG"
        },
        {
          "name": "Durvalumab",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "5-Flourouracil",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Nab-paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 76,
      "start_date": "2018-02-07",
      "completion_date": "2024-03-28",
      "has_results": false,
      "last_update_posted_date": "2024-08-21",
      "last_synced_at": "2026-10-15T03:46:54.112Z",
      "location_count": 6,
      "location_summary": "Lafayette, Indiana • Oklahoma City, Oklahoma • Nashville, Tennessee + 3 more",
      "locations": [
        {
          "city": "Lafayette",
          "state": "Indiana"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03421353"
    },
    {
      "nct_id": "NCT02630186",
      "title": "A Phase 1b/2 Study of Safety and Efficacy of Rociletinib in Combination With MPDL3280A in Patients With Advanced or Metastatic EGFR-mutant NSCLC",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Non-small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Rociletinib",
          "type": "DRUG"
        },
        {
          "name": "MPDL3280A",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Clovis Oncology, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3,
      "start_date": "2016-02-24",
      "completion_date": "2017-09-05",
      "has_results": true,
      "last_update_posted_date": "2019-07-05",
      "last_synced_at": "2026-10-15T03:46:54.112Z",
      "location_count": 1,
      "location_summary": "Santa Monica, California",
      "locations": [
        {
          "city": "Santa Monica",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02630186"
    },
    {
      "nct_id": "NCT00047736",
      "title": "A Study With Tarceva and Chemotherapy vs. Chemotherapy Alone in Patients With Advanced Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Tarceva (erlotinib HCl)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genentech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "2001-07",
      "completion_date": "2003-07",
      "has_results": false,
      "last_update_posted_date": "2013-06-21",
      "last_synced_at": "2026-10-15T03:46:54.112Z",
      "location_count": 2,
      "location_summary": "Denver, Colorado",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00047736"
    },
    {
      "nct_id": "NCT04141644",
      "title": "Safety and Efficacy of Combination Osimertinib and Ipilimumab in Patients w EGFR Mutated NSCLC",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor (Disorder)"
      ],
      "interventions": [
        {
          "name": "Ipilimumab",
          "type": "DRUG"
        },
        {
          "name": "Osimertinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Utah",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2020-08-20",
      "completion_date": "2028-04-30",
      "has_results": false,
      "last_update_posted_date": "2026-05-19",
      "last_synced_at": "2026-10-15T03:46:54.112Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04141644"
    },
    {
      "nct_id": "NCT06400472",
      "title": "A Study of Sofe-M in Participants With Selected Advanced Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Ovarian Neoplasms",
        "Endometrial Neoplasms",
        "Uterine Cervical Neoplasms",
        "Carcinoma, Non-Small-Cell Lung",
        "Triple Negative Breast Neoplasms",
        "Pancreatic Neoplasm",
        "Colorectal Neoplasms"
      ],
      "interventions": [
        {
          "name": "Sofe-M",
          "type": "DRUG"
        },
        {
          "name": "bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Itraconazole",
          "type": "DRUG"
        },
        {
          "name": "pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 575,
      "start_date": "2024-05-20",
      "completion_date": "2029-06",
      "has_results": false,
      "last_update_posted_date": "2026-10-07",
      "last_synced_at": "2026-10-15T03:46:54.112Z",
      "location_count": 11,
      "location_summary": "Scottsdale, Arizona • La Jolla, California • Atlanta, Georgia + 7 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        },
        {
          "city": "Mineola",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06400472"
    },
    {
      "nct_id": "NCT04209465",
      "title": "A Study of BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors.",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumor"
      ],
      "interventions": [
        {
          "name": "BDTX-189",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Black Diamond Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 91,
      "start_date": "2019-12-19",
      "completion_date": "2022-09-16",
      "has_results": true,
      "last_update_posted_date": "2025-04-17",
      "last_synced_at": "2026-10-15T03:46:54.112Z",
      "location_count": 24,
      "location_summary": "Scottsdale, Arizona • Long Beach, California • Orange, California + 20 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Lake Mary",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04209465"
    }
  ]
}